Authors

• Abhishek Bavle (ORCID: https://orcid.org/0000-0001-9927-8106)
• A. Wong
• Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
• Begoña P. Valderrama (ORCID: https://orcid.org/0000-0003-0175-1263)
• Seema Rao Gorla (ORCID: https://orcid.org/0009-0006-5256-2189)
• YI-TSUNG LU
• Sung Ho Park (ORCID: https://orcid.org/0000-0003-4856-7287)
• Su Wc
• Woo Kyun Bae
• T Powles
• Eiji Kikuchi
• Shuya Kandori
• Michiel S. Van der Heijden
• Jens Bedke
• Pongwut Danchaivijitr
• Xuesong Yu
• Se Hoon Park
• Shilpa Gupta
• Jian-Ri Li
• Jun Guo

Institutions

• Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
• Cleveland Clinic (US)
• Siriraj Hospital (TH)
• University of Tsukuba (JP)
• St. Marianna University School of Medicine (JP)
• Queen Mary University of London (GB)
• Pfizer (United States) (US)
• Peking University (CN)
• Mahidol University (TH)
• Severance Hospital (KR)
• Samsung Medical Center (KR)
• The Netherlands Cancer Institute (NL)
• Taichung Veterans General Hospital (TW)
• Peking University Cancer Hospital (CN)
• National University Cancer Institute, Singapore (SG)
• National Cancer Centre Singapore (SG)
• Chonnam National University Hwasun Hospital (KR)
• Hospital Universitario Virgen del Rocío (ES)
• National Cheng Kung University Hospital (TW)
• Yonsei University Health System (KR)
• Klinikum Stuttgart (DE)
• Astellas Pharma (United States) (US)
• Sungkyunkwan University (KR)
• National Cheng Kung University (TW)

Publication Details

Journal

International Journal of Clinical Oncology

Published

2026-01-21

DOI

https://doi.org/10.1007/s10147-025-02950-8

Citations

1

Primary Topic

Bladder and Urothelial Cancer Treatments

Type

article

Field-Weighted Citation Impact

39.15

Funders

• Pfizer
• Seagen
• Astellas Pharma
• Astellas Foundation for Research on Metabolic Disorders